Grepafloxacin (OPC-17116; 200 mg/kg; p.o.; Balb/c mice) displays good safety profile in terms of phototoxicity[2].
Grepafloxacin (25-200 mg/kg; p.o.; 5 days/week for 4 weeks; female C57BL6/J-Lyst bg-J/ mice/beige mice) has modest activities in both intranasal (IN) infection and intravenous (IV) Mycobacterium aviuminfection models[3].
| Animal Model: | Female Balb/c mice (5-6 weeks)[2] |
| Dosage: | 200 mg/kg |
| Administration: | Oral administration; once |
| Result: | Had mild and short-lived erythema and no changed auricular thickness. |
| Animal Model: | Female C57BL6/J-Lyst bg-J/ mice/beige mice with mycobacterium avium infection[3] |
| Dosage: | 25, 50, 100, and 200 mg/kg |
| Administration: | Oral administration; 5 days/week for 4 weeks |
| Result: | Had bactericidal activity and limited the growth of the bacteria. |
